AI-powered contentSome parts of this article are powered by AI.
Share this article
Gotrade News - Unicycive Therapeutics (UNCY) reported a third-quarter 2026 net loss attributable to common stockholders of $7.0 million, or $0.25 per share, according to the company's release filed with the SEC on Monday, November 16, 2026. It held approximately $59 million in cash, cash equivalents and marketable securities as of September 30.
Regular-session close on November 16, 2026, New York time. Prices and changes: Yahoo Finance, cross-checked against the closing price on Nasdaq.com.
Unicycive Therapeutics Earnings Details
The quarter's net loss compares with $6.0 million, or $0.33 per share, for the three months ended September 30, 2025. The company attributed the larger loss primarily to an increase in commercial launch expenses.
Research and development expense was $2.2 million, compared with $3.0 million a year earlier, driven primarily, the company said, by a $1.2 million decrease in development costs, partially offset by a $0.5 million increase in non-cash stock-based compensation. General and administrative expense was $6.6 million, compared with $4.4 million, including a $1.4 million increase related to commercial launch preparation. Other income was $1.8 million, compared with $1.3 million, which the company attributed primarily to the change in fair value of its warrant liability.
The company said its cash position provides expected runway beyond 2027, including anticipated increased expenses related to the launch of oxylanthanum carbonate (OLC) should it receive approval.
Why It Matters for UNCY
OLC is the company's investigational phosphate binder for patients with chronic kidney disease on dialysis. In October, Unicycive announced that the U.S. Food and Drug Administration accepted the resubmission of its New Drug Application for OLC and set a Prescription Drug User Fee Act (PDUFA) target action date of Thursday, March 25, 2027. According to the company, the resubmission followed a Complete Response Letter received in June 2026 that cited deficiencies at its original drug product vendor and did not raise concerns regarding clinical efficacy or safety data. The resubmitted application remains subject to FDA review.
"With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA's review in order to support a potential launch," said Chief Executive Officer Shalabh Gupta, M.D. The company said it plans to bring key commercial leaders on board in the first quarter of 2027, and that it believes a Centers for Medicare & Medicaid Services final rule issued on Wednesday, October 28, 2026, creates favorable commercial launch conditions for OLC, if approved.
What to watch next: The FDA's PDUFA target action date for Unicycive's resubmitted New Drug Application for oxylanthanum carbonate (OLC) is Thursday, March 25, 2027.
This article is for education and information only and is not investment advice. Investment decisions are yours to make after your own research.
This article was written with the help of AI and checked by the Gotrade team before publishing.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.
M. Alfathan Rahman is a content writer with over 3 years of experience developing digital content strategies across various industries, including fintech. He has experience producing content for tax-related websites and financial education platforms. His focus areas include data research, and crafting financial articles that are informative, accurate, and accessible to investors of all experience levels.